Drugs Investment 'Will Cease in India' - Presented by: The Aol. On Network

The head of Novartis India, Ranjit Shahani, has said the company was "disappointed" that India's Supreme Court refused to grant a patent for an updated version of its cancer drug Glivec.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 15.91 0.06 ▲ 0.38%
SUNE $ 11.83 1.04 ▲ 9.64%
AAPL $ 110.32 2.02 ▼ 1.80%
XIV $ 24.56 0.12 ▲ 0.49%
QQQ $ 103.46 0.44 ▼ 0.42%
FCX $ 10.04 0.14 ▲ 1.41%
INTC $ 29.14 0.54 ▲ 1.89%
ITUB $ 7.18 0.15 ▲ 2.13%

As of 9/3/2015, 02:05 PM